A UNSW Sydney-led team of scientists has made an advance that could eventually lead to a cure for sickle cell anaemia and other blood disorders.
By introducing a beneficial natural mutation into blood cells using the gene-editing technique CRISPR, a UNSW Sydney-led team of scientists has been able to switch on production of foetal haemoglobin – an advance that could eventually lead to a cure for sickle cell anaemia and other blood disorders.
People with thalassaemia or sickle cell anaemia have damaged adult haemoglobin – the vital molecule that picks up oxygen in the lungs and transports it around the body – and they require life-long treatment with blood transfusions and medication.
However, people with these diseases who also carry the beneficial natural mutation – known as British-198 – have reduced symptoms, because the mutation switches on the foetal haemoglobin gene that is normally turned off after birth.
The extra foetal haemoglobin in their blood, which has a very strong affinity for oxygen, does the work of the defective adult haemoglobin.
“With CRISPR gene-editing we can now precisely cut and alter single genes within our vast genome,” says study senior author and UNSW molecular biologist Professor Merlin Crossley.
“Our laboratory has shown that introducing the beneficial mutation British-198 into blood cells using this technology substantially boosts their production of foetal haemoglobin.
“Because this mutation already exists in nature and is benign, this ‘organic gene therapy’ approach should be effective and safe to use to treat, and possibly cure serious blood disorders. However, more research is still needed before it can be tested in people,” he says.
The study by scientists from UNSW, the Japanese Red Cross Society and the RIKEN BioResource Centre in Japan, is published in the journal Blood.
The beneficial British-198 mutation, which was first identified in a large British family in 1974, involves a change in just a single letter of the genetic code.
Carriers of this mutation have foetal haemoglobins levels as high as 20% of total haemoglobin, while most people’s foetal haemoglobin levels fall to about 1% of total haemoglobin after birth.
The researchers also discovered how this British-198 mutation works. They found it creates a new binding site for a protein called KLF1 that turns blood genes on.
Mutations affecting adult haemoglobin production are among the most common of all genetic variations, with about 5% of the world’s population carrying a defective gene.
“To turn the new gene editing approach into a therapy for blood disorders, the British-198 mutation would have to be introduced into blood-forming stem cells from the patient,” says Professor Crossley.
“A large number of stem cells would have to be edited in order to repopulate the patients’ blood with genetically enhanced cells.”
The Latest on: Genome therapy
- Gene therapy cures patient with sickle cell diseaseon November 30, 2019 at 4:38 pm
Doctors are offering hope to thousands of people suffering from genetic disorders after using gene-editing technology on two adults ... Treatment can involve a lifelong regime of blood transfusions ...
- Primary Children’s Hospital launches center with ‘cutting-edge’ genetic technologieson November 29, 2019 at 3:34 pm
The new center, a collaboration between Primary Children’s Hospital, University of Utah Health and Intermountain Precision Genomics, will provide precision diagnosis, gene therapy and novel ...
- Genome Editing Services Market-Focus on CRISPR, 2019-2030on November 28, 2019 at 4:06 pm
An analysis highlighting potential strategic partners, segregated based on likelihood of entering into collaboration with CRISPR-based genome editing services providers. The analysis takes into ...
- Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Toolon November 28, 2019 at 4:12 am
DUBLIN, Nov. 28, 2019 /PRNewswire/ -- The "Genome Editing Services Market-Focus on CRISPR 2019-2030" report has been ... Recently, in July 2019, a first in vivo clinical trial for a CRISPR-based ...
- UMass Med School gene therapy shows promising early results in tackling Tay-Sachson November 27, 2019 at 4:13 pm
The second patient, who was around 6 months old when some of the gene therapy was injected into the thalamus region of the brain, about six months ago, has not degenerated further since then. Flotte ...
- CRISPR vs. Gene Therapy Round 1: What Investors Need to Knowon November 26, 2019 at 11:18 am
At the very least, the process can insert the gene into a precise location in the genome. More impressive -- and something that traditional gene therapy can't readily do -- CRISPR/Cas9 offers the ...
- Tests suggest potential therapy for a childhood leukemiaon November 26, 2019 at 7:23 am
“We investigated the function of the individual proteins in this genetic machinery and used this to identify key elements that could be targeted through therapy,” explains Huang. Using the ‘gene ...
- Gene Therapy Market Expected to Grow with a CAGR of 16.92% During the Forecast Period, 2019-2024 - ResearchAndMarkets.comon November 26, 2019 at 6:53 am
Gene therapy is an experimental technique that involves the introduction of DNA usually containing a functional gene into a patient for the treatment of genetic disorders. Gene therapy works by ...
- Identification of novel genetic variants predisposing to familial oral squamous cell carcinomason November 25, 2019 at 7:11 pm
Here, we analyzed whole-genome sequences of a family with autosomal dominant expression of oral tongue ... She was treated with multiple surgical excisions, radiation therapy and chemotherapy. She ...
- Speeding cell, gene therapy developmenton November 25, 2019 at 4:13 am
Recent years have seen dramatic breakthroughs in cell and gene therapy, with new approaches attacking genetic maladies like sickle cell disease by repairing or overriding the DNA mutations that cause ...
via Google News and Bing News